Cliramitug (ALXN2220/NI006)
ATTR Cardiomyopathy (ATTR-CM)
Phase 3Active
Key Facts
About Neurimmune
Neurimmune is a Swiss, privately-held biotech founded in 2006, specializing in discovering and developing first-in-class antibody therapeutics for protein aggregation diseases. Its core Reverse Translational Medicine™ platform analyzes immune cells from elderly donors to generate fully human antibodies with high selectivity and low immunogenicity risk. The company has built a diversified clinical-stage pipeline targeting ATTR-CM, ALS, and Alzheimer's, advancing programs through strategic partnerships with major pharma while retaining early-stage innovation autonomy.
View full company profile